Talis BiomedicalTLIS
13F holders, Q1 2024 (March 31)18holders
2famous investors
$8.75avg. 13F price*
At the end of Q1 2024, 18 institutions reported holding Talis Biomedical Corp. (TLIS) in their 13F filings. The largest holders were Baker Bros. Advisors LP ($4.4M), Greenlight Capital (DME Capital Management) ($1.3M) and BML Capital Management, LLC ($374K). 2 famous investors held it, including David Einhorn (0.1% of Greenlight Capital (DME Capital Management)'s portfolio) and Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Talis Biomedical Corp.
- CUSIP
- 87424L207
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $93K |
| Exits | 2 | $87K |
Ownership 18 holders
| Baker Bros. Advisors LP | 0.06% | No change | 508,323 | $4.4M |
| Greenlight Capital (DME Capital Management) | 0.06% | No change | 149,052 | $1.3M |
| BML Capital Management, LLC | 0.25% | No change | 42,743 | $374K |
| Vanguard Group Inc. | 0.00% | No change | 31,013 | $271K |
| Susquehanna International Group, LLP | 0.00% | Add +11.9% | 17,431 | $153K |
| Prelude Capital Management, LLC | 0.01% | No change | 14,928 | $131K |
| Geode Capital Management, LLC | 0.00% | Add +5.4% | 11,890 | $104K |
| Renaissance Technologies | 0.00% | New | 10,299 | $90K |
| BlackRock Inc. | 0.00% | Reduce -54.8% | 4,711 | $41K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -6.2% | 927 | $8K |
| Morgan Stanley | 0.00% | Add +71.2% | 635 | $6K |
| ADAR1 Capital Management, LLC | 0.00% | New | 300 | $3K |
| Osaic Holdings, Inc. | 0.00% | Add +16.2% | 122 | $1K |
| UBS Group AG | 0.00% | Reduce -5.5% | 120 | $1K |
| Larson Financial Group LLC | 0.00% | No change | 14 | $123 |
| Wells Fargo & Company | 0.00% | No change | 13 | $114 |
| JPMorgan Chase & Co. | 0.00% | Add +50.0% | 3 | $26 |
| Qube Research & Technologies Ltd | 0.00% | No change | 2 | $18 |
"% of holder's portfolio" is TLIS's weight in each manager's 13F, not the share of Talis Biomedical Corp. the manager owns.